Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes

Abstract

Drug-induced cardiotoxicity and hepatotoxicity are major causes of drug attrition. To decrease late-stage drug attrition, pharmaceutical and biotechnology industries need to establish biologically relevant models that use phenotypic screening to detect drug-induced toxicity in vitro. In this study, we sought to rapidly detect patterns of cardiotoxicity using high-content image analysis with deep learning and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). We screened a library of 1280 bioactive compounds and identified those with potential cardiotoxic liabilities in iPSC-CMs using a single-parameter score based on deep learning. Compounds demonstrating cardiotoxicity in iPSC-CMs included DNA intercalators, ion channel blockers, epidermal growth factor receptor, cyclin-dependent kinase, and multi-kinase inhibitors. We also screened a diverse library of molecules with unknown targets and identified chemical frameworks that show cardiotoxic signal in iPSC-CMs. By using this screening approach during target discovery and lead optimization, we can de-risk early-stage drug discovery. We show that the broad applicability of combining deep learning with iPSC technology is an effective way to interrogate cellular phenotypes and identify drugs that may protect against diseased phenotypes and deleterious mutations.

Data availability

Our RNA-Seq data has been deposited on the Gene Expression Omnibus (GEO) database. GEO Submission (GSE172181):https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172181

The following data sets were generated

Article and author information

Author details

  1. Francis Grafton

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Francis Grafton, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  2. Jaclyn Ho

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Jaclyn Ho, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  3. Sara Ranjbarvaziri

    Pediatrics (Cardiology),, Stanford University, Palo Alto, United States
    Competing interests
    No competing interests declared.
  4. Farshad Farshidfar

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Farshad Farshidfar, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  5. Anastasiia Budan

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Anastasiia Budan, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  6. Stephanie Steltzer

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Stephanie Steltzer, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  7. Mahnaz Maddah

    -, Dana Solutions, Palo Alto, United States
    Competing interests
    Mahnaz Maddah, is affiliated with Dana Solutions. The author has no other competing interests to declare..
  8. Kevin E Loewke

    -, Dana Solutions, Palo Alto, United States
    Competing interests
    Kevin E Loewke, is affiliated with Dana Solutions. The author has no other competing interests to declare..
  9. Kristina Green

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Kristina Green, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  10. Snahel Patel

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Snahel Patel, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  11. Tim Hoey

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Tim Hoey, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  12. Mohammad Ali Mandegar

    Tenaya Therapeutics, Tenaya Therapeutics, South San Francisco, United States
    For correspondence
    mandegar@tenayathera.com
    Competing interests
    Mohammad Ali Mandegar, is an employee of Tenaya Therapeutics and has stock holdings in the company..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5323-7891

Funding

No external funding was received for this work

Reviewing Editor

  1. Arduino A Mangoni, Flinders Medical Centre, Australia

Version history

  1. Preprint posted: March 24, 2021 (view preprint)
  2. Received: March 24, 2021
  3. Accepted: July 27, 2021
  4. Accepted Manuscript published: August 2, 2021 (version 1)
  5. Version of Record published: August 16, 2021 (version 2)

Copyright

© 2021, Grafton et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,982
    views
  • 571
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Francis Grafton
  2. Jaclyn Ho
  3. Sara Ranjbarvaziri
  4. Farshad Farshidfar
  5. Anastasiia Budan
  6. Stephanie Steltzer
  7. Mahnaz Maddah
  8. Kevin E Loewke
  9. Kristina Green
  10. Snahel Patel
  11. Tim Hoey
  12. Mohammad Ali Mandegar
(2021)
Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes
eLife 10:e68714.
https://doi.org/10.7554/eLife.68714

Share this article

https://doi.org/10.7554/eLife.68714

Further reading

    1. Stem Cells and Regenerative Medicine
    Magali Seguret, Patricia Davidson ... Jean-Sébastien Hulot
    Research Article

    We developed a 96-well plate assay which allows fast, reproducible, and high-throughput generation of 3D cardiac rings around a deformable optically transparent hydrogel (polyethylene glycol [PEG]) pillar of known stiffness. Human induced pluripotent stem cell-derived cardiomyocytes, mixed with normal human adult dermal fibroblasts in an optimized 3:1 ratio, self-organized to form ring-shaped cardiac constructs. Immunostaining showed that the fibroblasts form a basal layer in contact with the glass, stabilizing the muscular fiber above. Tissues started contracting around the pillar at D1 and their fractional shortening increased until D7, reaching a plateau at 25±1%, that was maintained up to 14 days. The average stress, calculated from the compaction of the central pillar during contractions, was 1.4±0.4 mN/mm2. The cardiac constructs recapitulated expected inotropic responses to calcium and various drugs (isoproterenol, verapamil) as well as the arrhythmogenic effects of dofetilide. This versatile high-throughput assay allows multiple in situ mechanical and structural readouts.

    1. Stem Cells and Regenerative Medicine
    Shintaro Watanuki, Hiroshi Kobayashi ... Keiyo Takubo
    Research Article

    Metabolic pathways are plastic and rapidly change in response to stress or perturbation. Current metabolic profiling techniques require lysis of many cells, complicating the tracking of metabolic changes over time after stress in rare cells such as hematopoietic stem cells (HSCs). Here, we aimed to identify the key metabolic enzymes that define differences in glycolytic metabolism between steady-state and stress conditions in murine HSCs and elucidate their regulatory mechanisms. Through quantitative 13C metabolic flux analysis of glucose metabolism using high-sensitivity glucose tracing and mathematical modeling, we found that HSCs activate the glycolytic rate-limiting enzyme phosphofructokinase (PFK) during proliferation and oxidative phosphorylation (OXPHOS) inhibition. Real-time measurement of ATP levels in single HSCs demonstrated that proliferative stress or OXPHOS inhibition led to accelerated glycolysis via increased activity of PFKFB3, the enzyme regulating an allosteric PFK activator, within seconds to meet ATP requirements. Furthermore, varying stresses differentially activated PFKFB3 via PRMT1-dependent methylation during proliferative stress and via AMPK-dependent phosphorylation during OXPHOS inhibition. Overexpression of Pfkfb3 induced HSC proliferation and promoted differentiated cell production, whereas inhibition or loss of Pfkfb3 suppressed them. This study reveals the flexible and multilayered regulation of HSC glycolytic metabolism to sustain hematopoiesis under stress and provides techniques to better understand the physiological metabolism of rare hematopoietic cells.